Human tear lysozyme. II. Quantitative determination with standard Schirmer strips.

Quantitative tear lysozyme assay in units of activity per microlitre. Br J Ophthalmol (1976) 1.56

Normal tear protein profiles and age-related changes. Br J Ophthalmol (1984) 1.23

The aging lacrimal gland: changes in structure and function. Ocul Surf (2008) 1.04

Uptake and loss of tears from filter paper discs employed in lysozyme tests. Br J Ophthalmol (1979) 0.99

Aging and the lacrimal system. Br J Ophthalmol (1997) 0.97

Lysozyme deficiency-an inherited disorder of rabbits. Am J Pathol (1974) 0.97

Fluid uptake in Schirmer papers and its relevance to their employment in tear collection for lysozyme tests. Br J Ophthalmol (1980) 0.90

Lysozyme in the tears of newborn babies. Arch Dis Child (1979) 0.88

Immunoassay of tear lysozyme in conjunctival diseases. Br J Ophthalmol (1982) 0.80

Biological variations of lysozyme concentration in the tear fluids of healthy persons. Br J Ophthalmol (1986) 0.79

Modification of the tear function index and its use in the diagnosis of Sjögren's syndrome. Br J Ophthalmol (2001) 0.76

Immunological sequelae of intrauterine infection. Clin Exp Immunol (1981) 0.75

Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene (2006) 4.06

Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J Immunol (1979) 1.80

Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy (2011) 1.73

Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res (2001) 1.59

Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res (2001) 1.59

Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol (1988) 1.54

Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.53

Evidence for several cell populations active in antibody dependent cellular cytotoxicity. J Immunol (1973) 1.44

Studies on the mechanism of natural killer (NK) cell-mediated cytotoxicity (CMC). I. Release of cytotoxic factors specific for NK-sensitive target cells (NKCF) during co-culture of NK effector cells with NK target cells. J Immunol (1982) 1.42

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm (1997) 1.40

Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. J Immunol (1992) 1.39

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. I. Defective trigger on NK cells for NKCF production by target cells, and partial restoration by IL 2. J Immunol (1986) 1.34

Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene (2009) 1.34

Cellular immunoadsorbents: a simplified technique for separation of lymphoid cell populations. J Immunol (1974) 1.34

Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33

The SJL/J T cell response to both spontaneous and transplantable syngeneic reticulum cell sarcoma is mediated predominantly by the V beta 17a+ T cell clonotype. J Exp Med (1988) 1.30

Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol (1996) 1.30

Mechanism of cell-mediated cytotoxicity at the single cell level. II. Evidence for first-order kinetics of T cell-mediated cytolysis and for heterogeneity of lytic rate. J Immunol (1979) 1.29

Selective lysis of NK-sensitive target cells by a soluble mediator released from murine spleen cells and human peripheral blood lymphocytes. J Immunol (1981) 1.26

Studies on the induction and expression of T cell-mediated immunity. X. Inhibition by Lyt 2,3 antisera of cytotoxic T lymphocyte-mediated antigen-specific and -nonspecific cytotoxicity: evidence for the blocking of the binding between T lymphocytes and target cells and not the post-binding cytolytic steps. J Immunol (1980) 1.25

Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J Biol Chem (1989) 1.25

Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol (1999) 1.24

Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer (2002) 1.22

Mode of action of interferon-mediated modulation of natural killer cytotoxic activity: recruitment of pre-NK cells and enhanced kinetics of lysis. J Immunol (1980) 1.21

Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity. J Immunol (1987) 1.15

Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res (1995) 1.15

Histamine-receptor leucocytes (HRL). Organ and lymphoid subpopulation distribution in man. Clin Exp Immunol (1977) 1.13

Histamine receptor-bearing leukocytes (HRL). I. Detection of histamine receptor-bearing cells by rosette formation with histamine-coated erythrocytes. J Immunol (1974) 1.13

Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anticancer Agents (2003) 1.13

Studies on the mechanism of natural killer cytotoxicity. II. coculture of human PBL with NK-sensitive or resistant cell lines stimulates release of natural killer cytotoxic factors (NKCF) selectively cytotoxic to NK-sensitive target cells. J Immunol (1983) 1.13

Concanavalin A-mediated activation of antigen-primed lymphocytes into secondary cytotoxic lymphocytes. J Exp Med (1977) 1.13

Antibody-dependent cellular cytotoxicity against HIV-coated target cells by peripheral blood monocytes from HIV seropositive asymptomatic patients. J Immunol (1990) 1.13

Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol (1997) 1.11

Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol (1995) 1.11

Antibody-dependent cellular cytotoxicity (ADCC)-mediated destruction of human immunodeficiency virus (HIV)-coated CD4+ T lymphocytes by acquired immunodeficiency syndrome (AIDS) effector cells. J Clin Immunol (1988) 1.07

Lectin-dependent cellular cytotoxicity in man. Transplantation (1977) 1.06

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene (2007) 1.04

Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol (1995) 1.04

Antibody dependent cellular cytotoxicity: cytotoxicity mediated by non t-lymphocytes. Clin Immunol Immunopathol (1974) 1.03

Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J Immunol (2001) 1.03

Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol (1991) 1.03

Specific antibodies to dinucleotides and trinucleotides. Eur J Biochem (1972) 1.02

Mechanism of cell-mediated cytotoxicity at the single cell level. IV. Natural killing and antibody-dependent cellular cytotoxicity can be mediated by the same human effector cell as determined by the two-target conjugate assay. J Immunol (1982) 1.02

Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene (2006) 1.02

Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun (1999) 1.02

The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol Immunother (1997) 1.01

Proteins in human tears. I. Immunoelectrophoretic patterns. Arch Ophthalmol (1969) 0.99

Specific enhancement of tumor growth and depression of cell-mediated immunity following sensitization to soluble tumor antigens. Cancer Res (1976) 0.99

2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model. Clin Immunol (2008) 0.98

Regulation of B cell maturation and differentiation. I. Suppression of pokeweed mitogen-induced B cell differentiation by tumor necrosis factor (TNF). J Immunol (1987) 0.98

Prolonged asymptomatic states in HIV-seropositive persons with 50 CD4+ T-cells/mm3: preliminary psychoimmunologic findings. J Acquir Immune Defic Syndr (1993) 0.97

Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer (1999) 0.97

Mechanism of cell-mediated cytotoxicity at the single cell level. VIII. Kinetics of lysis of target cells bound by more than one cytotoxic T lymphocyte. J Immunol (1984) 0.96

Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer (1994) 0.96

Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia (2008) 0.96

Human tear lysozyme. 3. Preliminary study on lysozyme levels in subjects with smog eye irritation. Am J Ophthalmol (1968) 0.96

Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res (1993) 0.95

Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. J Immunol (1999) 0.95

Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cell Immunol (1982) 0.95

Purification and characterization of cytolytic and noncytolytic human natural killer cell subsets. Proc Natl Acad Sci U S A (1990) 0.94

Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin. Int J Oncol (1998) 0.94

CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. J Immunol (2000) 0.93

The SJL/J spontaneous reticulum cell sarcoma: new insights in the fields of neoantigens, host-tumor interactions, and regulation of tumor growth. Adv Cancer Res (1983) 0.93

Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res (1995) 0.93

Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clin Cancer Res (1997) 0.92

Frequency determination of killer cells by a single-cell cytotoxic assay. Methods Enzymol (1983) 0.92

Immunological unresponsiveness induced in adult mice to synthetic polypeptides built on multichain polyproline and multichain polyalanine. Immunochemistry (1974) 0.92

Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res (1999) 0.92

Autoimmunity and aging: the age-related response of mice of a long-lived strain to trinitrophenylated syngeneic mouse red blood cells. J Immunol (1976) 0.92

Differential secretion of TNF-alpha and IFN-gamma by human peripheral blood-derived NK subsets and association with functional maturation. J Clin Immunol (1996) 0.92

Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF). J Immunol (1983) 0.91

Direct estimation of frequency of cytotoxic T lymphocytes by a modified plaque assay. Nature (1976) 0.91

Studies on the induction and expression of T cell-mediated immunity. I. Blocking of cell-mediated cytolysis by membrane antigens. J Immunol (1974) 0.91

Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol (2001) 0.90

Studies on the induction and expression of T cell-mediated immunity. VIII. Effector-target junctions and target cell membrane disruption during cytolysis. Cell Immunol (1979) 0.90

Human tear lysozyme. I. Purification, physicochemical, and immunochemical characterization. J Lab Clin Med (1967) 0.90

MHC-Class I antigens regulate both the function and the survival of human peripheral blood NK cells: role of endogenously secreted TNF-alpha. Clin Immunol (2000) 0.90

Studies on the induction and expression of T cell-mediated immunity. XII. The concomitant loss and recovery of membrane-associated Lyt-2 antigens, lymphocyte-target cell binding, and the antigen-specific and -nonspecific cytotoxic activity of alloimmune T lymphocytes after treatment with trypsin. J Immunol (1981) 0.90

Studies on the mechanism of natural killer cell-mediated cytotoxicity. VII. functional comparison of human natural killer cytotoxic factors with recombinant lymphotoxin and tumor necrosis factor. J Immunol (1987) 0.89

Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. Gynecol Oncol (1999) 0.89

Capacity of tumor necrosis factor to bind and penetrate membranes is pH-dependent. J Immunol (1988) 0.89

Antibody-mediated in vivo suppression of EL4 leukemia in a syngeneic host. J Natl Cancer Inst (1974) 0.89

HTLV-1 gene expression in adult T-cell leukemia cells elicits an NK cell response in vitro and correlates with cell rejection in SCID mice. Virology (1996) 0.89

Studies on the induction and expression of T cell-mediated immunity. XI. Inhibition of the "lethal hit" in T cell-mediated cytotoxicity by heterologous rat antiserum made against alloimmune cytotoxic T lymphocytes. J Immunol (1981) 0.89

Mechanism of cell-mediated cytotoxicity at the single cell level. III. Evidence that cytotoxic T lymphocytes lyse both antigen-specific and -nonspecific targets pretreated with lectins or periodate. J Immunol (1981) 0.88

Studies on the induction and expression of T cell-mediated immunity. IV. Non-overlapping populations of alloimmune cytotoxic lymphocytes with specificity for tumor-associated antigens and transplantation antigens. J Immunol (1975) 0.88

Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. J Immunother (2001) 0.87

Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol (2001) 0.87

Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol (1997) 0.87

Structural basis for immune recognition of lysozymes. I. Effect of cyanogen bromide on hen egg-white lysozyme. Biochemistry (1969) 0.87

Studies on the induction and expression of T cell-mediated immunity. II. Antiserum blocking of cell-mediated cytolysis. J Immunol (1974) 0.87

Immune functions characteristic of SJL/J mice and their association with age and spontaneous reticulum cell sarcoma. Cancer Res (1976) 0.87

Role of natural killer cytotoxic factors in the mechanism of target-cell killing by natural killer cells. J Clin Immunol (1986) 0.87

Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J Urol (1994) 0.87

Expression of hybrid Ia molecules on the cell surface of reticulum cell sarcomas that are undetectable on host SJL/J lymphocytes. J Exp Med (1981) 0.87

Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Clin Cancer Res (2001) 0.87

Effect of altered membrane fluidity on NK cell-mediated cytotoxicity. I. Selective inhibition of the recognition or post recognition events in the cytolytic pathway of NK cells. J Immunol (1985) 0.87